Business
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Acad
About this update from Alterity Therapeutics Ltd.
[{"type":"image","alt":"ALTERITY THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"ALTERITY THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7YAvEB_IaVX9uXkeY1FY4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62","width":222,"height":56}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Academy of Neurology (AAN) Annual Meeting taking place April 18-22, 2026 in Chicago, IL, USA.","length":589,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:15%;width:15%;min-width:15%;","val":[{"type":"text","content":"Session:","length":8,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;","val":[{"type":"text","content":"Late-breaking Science 2","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"val":[{"type":"text","content":"Type:","length":5,"tagName":"p"}]},{"val":[{"type":"text","content":"Oral Presentation","length":17,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Title:","length":6,"tagName":"p"}]},{"val":[{"type":"text","content":"ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale","length":104,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Date/Time:","length":10,"tagName":"p"}]},{"val":[{"type":"text","content":"Tuesday, April 21, 2026, 6:21 PM CT","length":35,"tagName":"p"}]}]}],"length":214},{"type":"text","content":"About Alterity Therapeutics Limited ","length":35,"tagName":"p"},{"type":"text","content":"Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodeg...